IGM Biosciences, Inc.
IGM Biosciences, Inc. (IGMS): 134 pipeline candidates · ~3 mo cash runway · 92 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
3.2 months
D/E 0.06
Lead: Phase 3
134 candidates
N/A
N/A
A transparent, data-derived signal for IGM Biosciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$30.6M
Quarterly Burn
$50.8M
Runway
3.2 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (134 candidates)
| Drug | Phase |
|---|---|
| 5 FU bolus | Phase 2 |
| 5 FU continuous | Phase 2 |
| 5-FU | Phase 4 |
| Adagrasib | Phase 1 |
| AK112 | Phase 2 |
| AK119 | Phase 2 |
| Amivantamab | Phase 2 |
| Amivantamab + FOLFIRI | Phase 3 |
| Amivantamab IV | Phase 2 |
| Aplitabart | Phase 1 |
Showing 10 of 134 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in IGM Biosciences, Inc.'s pipeline?
IGM Biosciences, Inc. (IGMS) has 134 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is IGM Biosciences, Inc.'s lead drug candidate?
IGM Biosciences, Inc.'s most advanced tracked candidate is 5 FU bolus (Phase 2) for Metastatic Colorectal Carcinoma (mCRC).
What is IGM Biosciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, IGM Biosciences, Inc. has approximately 3.2 months of cash runway.
Who is the CEO of IGM Biosciences, Inc.?
Chief Executive Officer is the chief executive officer of IGM Biosciences, Inc. (IGMS).
Get the full picture on IGM Biosciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.